

REMARKS

This Amendment is in response to the Examiner's Notice of Allowance mailed May 4, 2006. By this amendment, Claim 7 is cancelled and Claims 20-23 are newly added.

Claim 7 does not have antecedent support due to the previous amendment to Claim 6 and is therefore cancelled.


Claims 20-23 are newly presented in response to the Notice of Allowance. Support for new Claims 20-23 is found in the Specification as originally filed and does not constitute new matter. In particular, new Claims 20-23 are directed to pharmaceutical compositions of the invention comprising one or more pharmaceutically acceptable excipient(s) and a therapeutically effective amount of a compound of formula (II) as defined in allowed Claims 2-5. Applicants respectfully submit that these new claims do not require a new search or examination since the scope of each new claim is narrower than the scope of allowed Claim 6. Furthermore, the scope of the compounds of formula (II) in new Claims 20-23 is the same as the scope of the compounds in allowed Claims 2-5, respectively. Accordingly, Applicants respectfully request the entry of this Amendment in full.

The Director is authorized to charge any additional fees due by way of this Amendment, or credit any overpayment, to Deposit Account No. 19-1090.

Respectfully submitted,

John G. Bauman et al.

SEED Intellectual Property Law Group PLLC



Carol J. Roth

Registration No. 32,783

CJR:cw

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031
794295